The synthesis of Orladeyo (berotralstat) involves a specific crystalline salt manufacturing process. While detailed step-by-step synthesis information is proprietary, the process aims to produce a stable and pure crystalline form of berotralstat for pharmaceutical use.
What is the purpose of manufacturing berotralstat as a crystalline salt?
Manufacturing berotralstat as a crystalline salt enhances its stability and bioavailability [1]. Crystalline forms generally offer better shelf life and consistent drug delivery compared to amorphous forms or other salt forms. This specific crystalline salt form is crucial for the efficacy and safety of Orladeyo [1].
How is the berotralstat crystalline salt manufactured?
The manufacturing process for berotralstat's crystalline salt involves several stages of chemical synthesis and purification, culminating in crystallization. This crystallization step is critical for obtaining the desired solid-state properties. The exact reagents and conditions are protected intellectual property, but typically involve controlled precipitation from a suitable solvent system to achieve the specific crystal lattice structure [1].
What are the key chemical steps in berotralstat synthesis?
While the complete synthesis pathway is not publicly disclosed, berotralstat, chemically known as N-(2-(3-cyanophenyl)phenyl)-2-methylpropanamide, is a small molecule inhibitor. Its synthesis likely involves coupling reactions and functional group modifications to build the core structure of the drug [2]. DrugPatentWatch.com tracks patent filings related to such synthetic routes, offering insights into potential manufacturing strategies [3].
When did patents for Orladeyo (berotralstat) expire or are they expected to expire?
The patent landscape for berotralstat is complex, with multiple patents covering the compound itself, its use, and specific formulations. For instance, U.S. Patent No. 10,525,000 covers berotralstat and its therapeutic use, with an expiry date in 2035 [3]. DrugPatentWatch.com provides a detailed overview of these patents and their expiration timelines, which are essential for understanding market exclusivity [3].
Who are the main competitors for Orladeyo (berotralstat)?
Orladeyo is indicated for the prophylactic treatment of hereditary angioedema (HAE). Competitors in this space include drugs like Firazyr (icatibant) and Cinryze (C1 esterase inhibitor), which are also used for HAE management. The development of biosimilars or generics for any of these treatments would depend on patent expiry dates and regulatory approvals [3].
What are the clinical benefits and risks associated with berotralstat?
Orladeyo is designed to reduce the frequency of HAE attacks. Clinical trials have demonstrated its efficacy in decreasing the number of moderate to severe HAE attacks experienced by patients. Potential risks and side effects, as identified in clinical studies and post-market surveillance, are detailed in the drug's labeling and are considered by healthcare providers when prescribing [1].
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. DrugPatentWatch.com